CSIMarket
 


Eagle Pharmaceuticals inc   (EGRX)
Other Ticker:  
 

Eagle Pharmaceuticals Inc 's Tangible Leverage Ratio

EGRX's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to repayements of liabilities of -10.83% Eagle Pharmaceuticals Inc improved Tangible Leverage Ratio in second quarter 2023 to 1.53, above the Eagle Pharmaceuticals Inc 's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the second quarter 2023, 240 other companies have achieved lower Tangible Leverage Ratio than Eagle Pharmaceuticals Inc in the II Quarter 2023. While Tangible Leverage Ratio total ranking has improved so far in the second quarter 2023 to 1036, from total ranking in the first quarter 2023 at 1363 .

Explain Tangible Leverage Ratio?
What is EGRX Market Share?
What are EGRX´s Total Liabilities?


EGRX Tangible Leverage Ratio (Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Tangible Equity Change 20.8 % -48.92 % -44.3 % -39.74 % -42.58 %
Y / Y Total Liabilities Change 9.73 % 64.42 % 123.35 % 111.55 % 100.65 %
Tangible Leverage Ratio MRQ 1.53 2.02 2.46 1.85 1.69
EGRX's Total Ranking # 1036 # 1363 # 1198 # 1358 # 1254
Seq. Tangible Equity Change 17.26 % 20.99 % -13.55 % -1.52 % -50.41 %
Seq. Total Liabilities Change -10.83 % -0.74 % 14.96 % 7.82 % 33.62 %



Tangible Leverage Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 241
Healthcare Sector # 461
Overall Market # 1036


Tangible Leverage Ratio Statistics
High Average Low
0.99 0.47 0.25
(Mar 31 2020)   (Jun 30 2015)




Financial Statements
Eagle Pharmaceuticals Inc 's Tangible Equity $ 100 Millions Visit EGRX's Balance sheet
Eagle Pharmaceuticals Inc 's Total Liabilities $ 153 Millions Visit EGRX's Balance sheet
Source of EGRX's Sales Visit EGRX's Sales by Geography


Cumulative Eagle Pharmaceuticals Inc 's Tangible Leverage Ratio

EGRX's Tangible Leverage Ratio for the trailling 12 Months

EGRX Tangible Leverage Ratio

(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Tangible Equity TTM Growth 20.8 % -48.92 % -44.3 % -39.74 % -42.58 %
Y / Y Total Liabilities TTM Growth 9.73 % 64.42 % 123.35 % 111.55 % 100.65 %
Tangible Leverage Ratio TTM 1.93 1.99 1.41 1.03 0.77
Total Ranking TTM # 6 # 1213 # 83 # 1348 # 5
Seq. Tangible Equity TTM Growth 17.26 % 20.99 % -13.55 % -1.52 % -50.41 %
Seq. Total Liabilities TTM Growth -10.83 % -0.74 % 14.96 % 7.82 % 33.62 %


On the trailing twelve months basis Due to repayements of liabilities of -10.83% Eagle Pharmaceuticals Inc decreased Tangible Leverage Ratio in the 12 months ending in II Quarter 2023 to 1.93, above the Eagle Pharmaceuticals Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry EGRX recorded the lowest Tangible Leverage Ratio. While Tangible Leverage Ratio total ranking has improved so far to 6, from total ranking in previous 12 month period at 1213.

Explain Tangible Leverage Ratio?
What is EGRX Market Share?
What are EGRX´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 6


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.68 0.47 0.35
(Mar 31 2023)   (March 31, 2016)




Companies with similar Tangible Leverage Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioJun 30 2023 MRQ Total LiabilitiesJun 30 2023 MRQ Tangible Equity
Opko Health Inc   4.00 $ 623.551  Millions$ 155.778  Millions
Mei Pharma Inc   3.85 $ 94.757  Millions$ 24.624  Millions
Biolinerx Ltd   3.83 $ 50.702  Millions$ 13.223  Millions
Iterum Therapeutics Plc  3.77 $ 23.641  Millions$ 6.268  Millions
Corbus Pharmaceuticals Holdings Inc   3.65 $ 34.721  Millions$ 9.521  Millions
Phibro Animal Health Corporation  3.50 $ 609.036  Millions$ 174.248  Millions
Horizon Therapeutics Public Limited Company  3.45 $ 3,459.139  Millions$ 1,003.856  Millions
Rockwell Medical inc   3.31 $ 28.509  Millions$ 8.607  Millions
Arcutis Biotherapeutics Inc   3.26 $ 240.181  Millions$ 73.696  Millions
Sarepta Therapeutics Inc   3.16 $ 2,339.490  Millions$ 741.411  Millions
Perrigo Company Plc  3.08 $ 5,597.200  Millions$ 1,817.800  Millions
Panbela Therapeutics Inc   3.07 $ 14.749  Millions$ 4.802  Millions
Oncotelic Therapeutics Inc   2.98 $ 17.697  Millions$ 5.938  Millions
Ani Pharmaceuticals Inc  2.98 $ 449.719  Millions$ 151.102  Millions
Trevena inc   2.97 $ 29.077  Millions$ 9.782  Millions
Tempest Therapeutics Inc   2.93 $ 14.708  Millions$ 5.012  Millions
Veru Inc   2.81 $ 40.808  Millions$ 14.510  Millions
Kala Bio inc   2.80 $ 49.008  Millions$ 17.492  Millions
Innovation Pharmaceuticals Inc   2.69 $ 5.478  Millions$ 2.039  Millions
Ibio inc   2.58 $ 25.826  Millions$ 9.993  Millions
Blueprint Medicines Corporation  2.56 $ 795.315  Millions$ 311.130  Millions
Marinus Pharmaceuticals Inc   2.48 $ 142.305  Millions$ 57.339  Millions
Mersana Therapeutics Inc   2.46 $ 221.200  Millions$ 89.800  Millions
Orgenesis Inc   2.43 $ 30.605  Millions$ 12.581  Millions
Cryoport inc   2.43 $ 486.395  Millions$ 199.955  Millions
Reviva Pharmaceuticals Holdings Inc   2.40 $ 3.883  Millions$ 1.621  Millions
Proqr Therapeutics N v   2.33 $ 108.072  Millions$ 46.357  Millions
Novartis Ag  2.27 $ 53,195.000  Millions$ 23,409.000  Millions
Reata Pharmaceuticals Inc   2.27 $ 198.223  Millions$ 87.291  Millions
Cyclacel Pharmaceuticals Inc   2.20 $ 11.306  Millions$ 5.136  Millions

Date modified: 2023-08-11T06:01:28+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com